company background image
A068270

Celltrion KOSE:A068270 Stock Report

Last Price

₩162.60k

Market Cap

₩22.6t

7D

-0.1%

1Y

-2.5%

Updated

04 Dec, 2023

Data

Company Financials +

A068270 Stock Overview

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea.

A068270 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Celltrion, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion
Historical stock prices
Current Share Price₩162,600.00
52 Week High₩184,100.00
52 Week Low₩131,000.00
Beta0.23
1 Month Change8.47%
3 Month Change10.91%
1 Year Change-2.53%
3 Year Change-56.40%
5 Year Change-22.93%
Change since IPO1,536.20%

Recent News & Updates

Recent updates

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

May 05
Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Mar 25
Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15
Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24
Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03
Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13
Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23
Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02
Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Shareholder Returns

A068270KR BiotechsKR Market
7D-0.1%-0.5%0.5%
1Y-2.5%-6.3%4.4%

Return vs Industry: A068270 exceeded the KR Biotechs industry which returned -6.3% over the past year.

Return vs Market: A068270 underperformed the KR Market which returned 4.4% over the past year.

Price Volatility

Is A068270's price volatile compared to industry and market?
A068270 volatility
A068270 Average Weekly Movement4.1%
Biotechs Industry Average Movement7.1%
Market Average Movement5.8%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market2.9%

Stable Share Price: A068270 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aHyong-Gi Kimhttps://www.celltrion.com

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial.

Celltrion, Inc. Fundamentals Summary

How do Celltrion's earnings and revenue compare to its market cap?
A068270 fundamental statistics
Market Cap₩22.64t
Earnings (TTM)₩603.80b
Revenue (TTM)₩2.30t

37.4x

P/E Ratio

9.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A068270 income statement (TTM)
Revenue₩2.30t
Cost of Revenue₩1.19t
Gross Profit₩1.11t
Other Expenses₩506.87b
Earnings₩603.80b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)4.35k
Gross Margin48.20%
Net Profit Margin26.20%
Debt/Equity Ratio19.7%

How did A068270 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

9%

Payout Ratio

Does A068270 pay a reliable dividends?

See A068270 dividend history and benchmarks
When do you need to buy A068270 by to receive an upcoming dividend?
Celltrion dividend dates
Ex Dividend DateDec 27 2023
Dividend Pay DateApr 24 2024
Days until Ex dividend23 days
Days until Dividend pay date142 days

Does A068270 pay a reliable dividends?

See A068270 dividend history and benchmarks